Individual Seed Projects
Utilizing the Immune Profile of Blood as a Biomarker for Transient Ischemic Attacks
- 300,000 people in the United States experience a TIA annually with over 10% suffering an ischemic stroke in the subsequent 90 days.
- No effective biomarker currently exists.
- Our approach identifies the immune profile of TIAs utilizing state of the art immune monitoring - Mass Cytometry by Time Of Flight Mass Spectrometry (CyTOF)
- Identification of these blood biomarkers will drastically change the current management of TIAs to prevent future strokes